Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -4.43 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 78.38 | 87.06 | 94.58 | — | 70.71 | 51.60 | 34.81 | 76.63 | 60.74 | 87.40 | 104.01 | 6.11 | 6.93 | 66.70 | 108.56 | — | — | — | — | — | — |
| — | +68.7% | +171.7% | — | +16.4% | -41.0% | -66.5% | +1154.2% | +776.0% | +31.0% | -4.2% | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | — | — | 99.91 | — | 140.25 | 92.85 | 12.96 | 7.90 | 6.79 | 23.57 | 13.94 | 3.64 | 1.76 | 1.84 | 2.54 | 3.87 | 4.05 | 4.29 | 5.18 | 9.46 | 13.33 |
| — | — | +670.9% | — | +1964.6% | +294.0% | -7.0% | +117.3% | +286.6% | +1179.9% | +449.3% | -6.0% | -56.6% | -57.1% | -51.0% | -59.1% | -69.6% | -68.2% | -81.0% | -21.3% | +337.8% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 45.9% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -90.5% | -2904.9% | -2196.2% | — | — | — | — | — | — |
| — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | +210.5% | +103.4% | +104.6% | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | -1425.7% | -1105.1% | -1163.7% | 8805.7% | -1006.0% | -1004.7% | -979.1% | -1811.5% | -1166.5% | -1354.0% | -1204.7% | -142.9% | -336.1% | -4853.6% | -4071.1% | — | — | — | — | — | — |
| — | -10.0% | -18.8% | +586.1% | +13.8% | +25.8% | +18.7% | -1168.0% | -247.1% | +72.1% | +70.4% | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | -1537.4% | -1671.8% | -1250.9% | 9174.1% | -1144.5% | -1073.5% | -1036.5% | -1816.8% | -1141.7% | -1339.2% | -1175.9% | -157.3% | -316.8% | -4755.7% | -3911.1% | — | — | — | — | — | — |
| — | -55.7% | -20.7% | +605.0% | -0.2% | +19.8% | +11.9% | -1055.2% | -260.4% | +71.8% | +69.9% | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -776.9% | — | -330.4% | — | -609.0% | -155.4% | -67.4% | -39.5% | -45.1% | -64.8% | -33.7% | -19.2% | -18.2% | -31.6% | -23.1% | -25.9% | -20.9% | -15.9% | -15.9% | -14.4% | -9.6% |
| — | — | -390.1% | — | -1251.3% | -140.0% | -100.2% | -105.9% | -147.5% | -105.1% | -45.5% | +26.0% | +13.0% | -98.9% | -45.7% | -80.4% | -117.6% | +50.2% | +23.7% | +31.8% | +86.7% | |
| ROA | -107.7% | -27.5% | -37.9% | -34.8% | -36.1% | -25.0% | -20.9% | -19.2% | -25.3% | -33.1% | -20.5% | -13.6% | -14.3% | -24.9% | -16.9% | -19.5% | -17.8% | -14.3% | -14.6% | -13.1% | -8.9% |
| — | -10.0% | -81.4% | -80.8% | -42.5% | +24.6% | -2.0% | -41.0% | -76.8% | -32.9% | -21.2% | +30.1% | +19.6% | -73.8% | -16.1% | -48.6% | -99.1% | +50.8% | +16.4% | +17.0% | +81.1% | |
| ROIC | -1565.6% | — | -277.2% | -402.2% | -206.6% | -110.1% | -160.4% | -168.3% | -118.2% | -123.2% | -97.7% | -66.5% | -105.5% | -175.8% | -162.9% | -1221.8% | -662.8% | -306.3% | -311.3% | -309.1% | -236.5% |
| — | — | -72.8% | -139.0% | -74.8% | +10.6% | -64.3% | -152.8% | -12.0% | +29.9% | +40.0% | +94.6% | +84.1% | +42.6% | +47.7% | -295.3% | -180.3% | +26.3% | -56.3% | — | +27.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 5.74 | — | 9.33 | 10.75 | 2.00 | 1.10 | 0.17 | 0.41 | 0.23 | 0.17 | 0.11 | 0.09 | 0.08 | 0.09 | 0.07 | 0.05 | 0.02 | 0.03 | 0.03 |
| — | — | +186.8% | — | +5488.8% | +2551.8% | +785.7% | +541.0% | +50.6% | +333.7% | +172.7% | +98.6% | +63.3% | +79.2% | +243.0% | +149.7% | +131.3% | +91.7% | -69.0% | -70.1% | -87.4% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.06 | 0.80 | 1.86 | 1.06 | 1.85 | 1.83 | 2.60 | 2.86 | 2.58 | 1.04 | 1.87 | 2.51 | 5.08 | 5.46 | 5.38 | 3.45 | 7.21 | 11.86 | 17.96 | 14.66 | 18.21 |
| — | -56.1% | -28.5% | -63.0% | -28.4% | +76.5% | +39.3% | +13.6% | -49.2% | -81.0% | -65.3% | -27.2% | -29.6% | -54.0% | -70.0% | -76.5% | -60.4% | -52.8% | +49.7% | +104.8% | +280.8% | |
| Quick Ratio | 1.06 | 0.80 | 1.86 | 1.06 | 1.85 | 1.83 | 2.60 | 2.86 | 2.58 | 1.04 | 1.87 | 2.51 | 5.08 | 5.46 | 5.38 | 3.45 | 7.21 | 11.86 | 17.96 | 14.66 | 18.21 |
| — | -56.1% | -28.5% | -63.0% | -28.4% | +76.5% | +39.3% | +13.6% | -49.2% | -81.0% | -65.3% | -27.2% | -29.6% | -54.0% | -70.0% | -76.5% | -60.4% | -52.8% | +49.7% | +104.8% | +280.8% | |
| Interest Coverage | -12.08 | -4.56 | -13.53 | -11.91 | -14.26 | -12.93 | -15.79 | — | — | — | — | — | — | — | — | — | — | — | — | -728.05 | -567.84 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying OCGN stock.
Ocugen, Inc.'s current P/E is -4.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Ocugen, Inc.'s current operating margin is -1425.7%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Ocugen, Inc.'s business trajectory between earnings reports.